Ruxolitinib (INCB018424) is an inhibitor of JAK1 and JAK2 used in the treatment of myelofibrosis. Discontinuation of therapy may be followed by a withdrawal reaction that can be severe. This syndrome may be mediated by rapid changes in cytokine activity.